On July 2, 2020, Shanghai, China - on the occasion of China's 25th anniversary, bringer Ingelheim, the world's leading pharmaceutical enterprise driven by innovation and research, recently announced the launch of China's external innovation cooperation center in Shanghai. The biggest highlight of Boehringer Ingelheim China external innovation cooperation center is that it has adopted the first "three in one" business model among multinational pharmaceutical enterprises, which integrates academic cooperation (cross-border Research), business development and licensing, and venture capital. Through this initiative, we will integrate the company's innovation experience and the unique technology and professional skills of its partners in their respective related fields, jointly develop innovative drugs and therapies, and let more innovative projects with Chinese imprint enrich the global R & D pipeline of Boehringer Ingelheim, and benefit more patients.
As a result, Gao Qifei, President and CEO of Greater China of Boehringer Ingelheim, also extended a warm invitation to the innovators in the biomedical industry in China
This year coincides with the 25th anniversary of the company's entry into China, during which the achievements can not be separated from innovation. In the next five years, the company will continue to increase investment in China, including the establishment of China's external innovation cooperation center, which will be listed as one of the strategic pillars of Boehringer Ingelheim! As a century old family business, we pursue a long-term vision of research and investment, committed to the development of a new generation of breakthrough therapies. We welcome partners from the life science community to join hands in innovation and jointly improve the lives of patients.Dr. Zhang Weiyi, director of China external innovation cooperation center of bringer Ingelheim, said:
At present, the whole Asian region is becoming a hot spot of biomedical research, among which the innovation strength of China's biomedical industry has been rapidly improved. Bringer Ingelheim's goal is to seize the opportunity to become the preferred partner in the innovation ecosystem of China's biomedical industry.
At present, Boehringer Ingelheim China external innovation cooperation center has cooperated with many Chinese academic institutions, including establishing strategic cooperation relations with Tsinghua University and Peking University on comprehensive cooperation and early scientific research. In addition, the center has established various cooperative relationships with several institutes and scientific research institutions of the Chinese Academy of Sciences. Through cooperation, some research results have been published in mainstream journals.
It is reported that the objective of the external innovation cooperation center is to bring Chinese innovation into the bringer Ingelheim drug discovery value chain, and seek external cooperation opportunities from the early stage to the mature stage for the company, so as to strengthen the company's core treatment field, meet the urgent medical needs or prepare for entering new strategic areas in the future.This year is also the 25th anniversary of bringer Ingelheim's entry into China. Looking forward to the future, the company will continue to increase investment in China, with a confirmed capital increase plan of up to 451 million euro in the next five years; the company will also carry out all-round layout innovation, including Bix, the digital innovation laboratory just announced in Shanghai in March this year, and the official launch of China's external innovation center today. With the launch and implementation of the "China key" project, bringer Ingelheim has become the first multinational pharmaceutical company to fully integrate China into the global early clinical development project. By promoting the synchronization of global innovative drugs in China, it is expected that 71 new products or new indications will be approved in China in the next 10 years.
Gao Qifei, President and CEO of Greater China of Boehringer Ingelheim, said:
As a multinational pharmaceutical enterprise driven by innovation, Boehringer Ingelheim will adhere to the mission of the company and work together with internal and external innovation partners to accelerate the pace of medical breakthrough in the future, improve the lives of patients and improve the health of human and animals.Bringer ingelham China
Headquartered in Shanghai, Boehringer Ingelheim China has more than 4500 employees nationwide. Its core business includes: human medicine, animal health, biopharmaceutical and health innovation division. In recent years, Boehringer Ingelheim has achieved sustained growth in China, and its development rate has exceeded the average market growth level, and has been awarded the "outstanding employer in China" certification for seven consecutive years. Bringer Ingelheim integrates the needs of Chinese patients into the global R & D strategy, and is committed to bringing more and better innovative products to Chinese patients earlier, so as to improve people's health and quality of life.
2020 coincides with the 25th anniversary of Boehringer Ingelheim's entry into China. China is one of the most important strategic markets of Boehringer Ingelheim. Based on "rooted in China, serving China", the company further cultivates the development and growth of Chinese market."